Evaluation of Canakinumab in High-Risk Former-Smokers

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Peter Shields
Study ID
NCT06038526
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 73 Years
Healthy Volunteers
Accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    Undergo buccal, nasal, and blood sample collection
  • Bronchoscopy — PROCEDURE
    Undergo bronchoscopy
  • Canakinumab — BIOLOGICAL
    Given SC
  • Carbon Monoxide Measurement — PROCEDURE
    Undergo CO testing
  • Survey Administration — OTHER
    Ancillary studies

Study Details

This phase II trial tests the impact of canakinumab on biologic samples (buccal, nasal, and blood) from former smokers with increased risk of cancer. Canakinumab blocks the activity of a protein called interleukin-1 beta (IL-1b), an agent of the inflammatory system and is used for the treatment of different non-cancer diseases (like auto-inflammatory diseases). Giving canakinumab may block the inflammatory system and could have positive effects to reduce cancer growth.

Key Dates

Start date
Mar 11, 2024
Status verified
May 2026
Primary completion
Jul 30, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Prevention (canakinumab, bronchoscopy)
    Patients undergo bronchoscopy over 30-60 minutes and receive canakinumab SC 60 minutes and 2 weeks after the initial bronchoscopy. Patients undergo an additional bronchoscopy on day 77. Patients undergo buccal, nasal, and blood sample collection and CO testing on study.

Primary Outcome Measure

Change in ASCs (apoptosis-associated speck-like protein containing a caspase activation and recruitment domain) [ Time Frame: At baseline and day 77 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Ohio State University Comprehensive Cancer CenterColumbusOhio43210-

Find similar trials in Columbus, OH

By condition

Related Studies